Back to Archived News
Skinvisible Granted Patent in South Korea
Tuesday, March 23, 2010
Growing Invisicare Patent Portfolio Solidifies the Value of Skinvisible's Products
Las Vegas, NV -- Skinvisible, Inc. (OTCBB: SKVI) announced today that the South Korean patent office has granted a patent for Invisicare®, the company's polymer delivery system for topical dermatology products.
A total of twenty claims have been granted in the Korean patent which protects Invisicare in the areas of 'Topical Composition', 'Topical Composition Precursor', and 'Methods for Manufacturing and Using'. This is the fifth comprehensive international patent that Skinvisible has received for Invisicare® in addition to the four United States patents already granted. To date patents have been granted in India, Australia, China and Japan with a number of technology and product-specific patents pending globally.
"This latest patent strengthens the Company's growing proprietary position internationally, allowing us to present patent-protected opportunities to global pharmaceutical and consumer goods companies," said Mr. Terry Howlett, President and CEO of Skinvisible. "It also offers growing validation of the value of our technology as this patent, along with our other international patents, offers coverage of not only the composition, but also the manufacturing process and the dermatology indications our Invisicare technology is used for."
Invisicare is the core technology in Skinvisible's portfolio of products. Skinvisible licenses it products on an exclusive basis to companies seeking new products in the areas such as acne, dermatitis, actinic keratosis, anti-inflammatories, analgesics and antimicrobials. In addition, the company has developed a number of patent-protected and patent-pending cosmeceuticals such as moisturizers, sunscreens and sunless tanners. Invisicare adds unique benefits to these products including binding the product to the skin resisting wash-off and perspiration, controlling the release of the active; fast or slow and in some cases decreasing the use of actives and decreasing irritation. Along with patent protection, Skinvisible's products provide added benefits to topically formulated dermatology and consumer products that require rejuvenation, and add benefits to combat competition and generics.
Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. www.skinvisible.com
This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending October 31, 2009).
Back to Archived News